136 results about "Contractility" patented technology

Techniques are provided for use in controlling rate-adaptive pacing within implantable medical devices such as pacemakers or implantable cardioverter-defibrillators (ICDs). In one example, a force-frequency relationship is determined for the heart of the patient, which is representative of the relationship between cardiac stimulation frequency and myocardial contractile force. To this end, various parameters are detected for use as surrogates for contractile force, including selected systolic pressure parameters and cardiogenic impedance parameters. Rate-adaptive pacing is then controlled based on the detected force-frequency relationship to, for example, deactivate rate-adaptive pacing if the slope and / or abscissa of the force-frequency relationship indicates significant contractility dysfunction within the patient. In other examples, rather than deactivating rate-adaptive pacing, control parameters are adjusted to render the rate-adaptive pacing less aggressive. In still other examples, trends in the slope and / or abscissa of the force-frequency relationship are monitored to detect contractility dysfunction and / or heart failure and titrate medications accordingly.

Systems and methods for noninvasive assessment of cardiac tissue properties and cardiac parameters using ultrasound techniques are disclosed. Determinations of myocardial tissue stiffness, tension, strain, strain rate, and the like, may be used to assess myocardial contractility, myocardial ischemia and infarction, ventricular filling and atrial pressures, and diastolic functions. Non-invasive systems in which acoustic techniques, such as ultrasound, are employed to acquire data relating to intrinsic tissue displacements are disclosed. Non-invasive systems in which ultrasound techniques are used to acoustically stimulate or palpate target cardiac tissue, or induce a response at a cardiac tissue site that relates to cardiac tissue properties and / or cardiac parameters are also disclosed.

Systems and methods for noninvasive assessment of cardiac tissue properties and cardiac parameters using ultrasound techniques are disclosed. Determinations of myocardial tissue stiffness, tension, strain, strain rate, and the like, may be used to assess myocardial contractility, myocardial ischemia and infarction, ventricular filling and atrial pressures, and diastolic functions. Non-invasive systems in which acoustic techniques, such as ultrasound, are employed to acquire data relating to intrinsic tissue displacements are disclosed. Non-invasive systems in which ultrasound techniques are used to acoustically stimulate or palpate target cardiac tissue, or induce a response at a cardiac tissue site that relates to cardiac tissue properties and / or cardiac parameters are also disclosed.

A multi-modal cardiotherapy device (100) includes an anti-arrhythmic unit (118) for delivering multiple types of anti-arrhythmic therapy to a heart, a cardiac contractility modulating unit (108) for delivering cardiac contractility modulating signals to the heart, and for applying anti-arrhythmic cardiac contractility modulating signal therapy to the heart, one or more sensing units (112) for sensing electrical signals related to electrical activity of the heart to provide an output signal, one or more detecting units (116) operatively connected to the sensing unit(s) (112) for detecting in the output signal cardiac events of the heart, a controller unit (106) operatively connected to the anti-arrhythmic unit (118), the cardiac contractility modulating unit (108) and the detecting unit(s) (116). The controller unit (106) processes the output of the detecting unit(s) (116) to detect a cardiac arrhythmia or indications of a possible arrhythmia in the heart and controls the application of anti-arrhythmic therapy, anti-arrhythmic cardiac contractility modulating signal therapy, and cardiac contractility modulating therapy to the heart. The device may be an implantable device or a non-implantable device. The device (100) may also include a pacing unit (102). Methods are disclosed for using the device for delivering multi-modal cardiotherapy to the heart.

A method and apparatus for assessment of cardiac contractility in a subject by recording precordial acceleration signals. This includes, but is not limited to, the method and apparatus of seismocardiography (SCG).

Embodiments of the invention provide a medical implant, and method for deploying the same, configured for placement in a body lumen such as a coronary sinus, as may be desired to treat a regurgitant mitral valve. The implant includes a proximal anchor, a distal anchor, and an elongate bridge extending between the proximal and distal anchors. The anchors are configured to be delivered to a desired deployment site within the body lumen in a collapsed or contracted condition and then expanded to engage the walls of the body lumen. The bridge is preferably a shape-changing member configured to contract after delivery into the coronary sinus for applying a compressive force to the annulus of the mitral valve. The proximal and distal anchoring mechanisms preferably overlap the proximal and distal end portions of the bridge, thereby providing the implant with a longer bridge having greater contraction.

Systems and methods for prediction and detection of circulatory shock using estimates or measurements of arterial blood pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, cardiac ejection fraction, cardiac contractility and ventricular end-diastolic volume are provided. These estimates and measurements are used to determine a type of circulatory shock. In some embodiments, the type of circulatory shock is determined to be one of septic shock, hypovolemic shock, anaphylactic shock, hemorrhagic shock, and cardiogenic shock.

The methods and systems for estimating cardiac ejection fraction, cardiac contractility, and ventricular end-diastolic volume on a beat-by-beat basis include observing arterial blood pressure waveforms to determine ventricular compliances for a pressure-volume loop in the ventricle. Uncalibrated or calibrated cardiac ejection fraction may be calculated from estimates of stroke volume and the ventricular compliances. Cardiac contractility may be calculated from estimates of a ventricular compliance. Uncalibrated or calibrated ventricular end-diastolic volume may also be calculated from estimates of stroke volume and the ventricular compliances. A set of calibration parameters for calibrating cardiac ejection fraction or ventricular end-diastolic volume may be estimated in a least-squares manner.

A method of modifying the force of contraction of at least a portion of a heart chamber, including providing a subject having a heart, comprising at least a portion having an activation, and applying a non-excitatory electric field having a given duration, at a delay after the activation, to the portion, which causes the force of contraction to be increased by a least 5%.

The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

A cardiac electro-stimulatory device and method for operating same in which stimulation pulses are distributed among a plurality of electrodes fixed at different sites of the myocardium in order to reduce myocardial hypertrophy brought about by repeated pacing at a single site and / or increase myocardial contractility. In order to spatially and temporally distribute the stimulation, the pulses are delivered through a switchable pulse output configuration during a single cardiac cycle, with each configuration comprising one or more electrodes fixed to different sites in the myocardium.

A method and apparatus for treating or preventing neurocardiogenic syncope is disclosed. Upon detection of bradycardia or a drop in blood pressure indicating the onset of syncope, electrostimulation pulses are delivered during the heart's refractory period. The pulses are non-excitatory but increase myocardial contractility and thereby increase cardiac output.

An implantable blood flow monitoring system for providing synchronized blood vessel flow and myocardial wall contractility data to an external monitor independent of transcutaneous leads. Synchronized electrocardiogram data allows and provides comprehensive monitoring. A means is provided for transmitting synchronized cardiac function data and blood flow data to a distant remote location to facilitate continual physician monitoring.

A cardiac electro-stimulatory device and method for operating same in which stimulation pulses are distributed among a plurality of electrodes fixed at different sites of the myocardium in order to reduce myocardial hypertrophy brought about by repeated pacing at a single site and / or increase myocardial contractility. In order to spatially and temporally distribute the stimulation, the pulses are delivered through a switchable pulse output configuration during a single cardiac cycle, with each configuration comprising one or more electrodes fixed to different sites in the myocardium.

The invention relates to the application of panaxoside Rh2, Ck and Rg3 to increase the heart contraction force, wherein the medicine compound comprises active panaxoside Rh2 and / or Ck and / or Rg3 and medicine carrier, to be made into injection, oral agent and film agent, to cure acute and low heart cardiac failure or reduced heart contraction force.

The invention provides a traditional Chinese medicine preparation for treating liver-depression qi-stagnation type viral myocarditis. The traditional Chinese medicine preparation comprises the following components in parts by weight: 10-20 parts of radix bupleuri, 10-20 parts of cape jasmine, 10-20 parts of fructus forsythiae, 10-20 parts of radix pseudostellariae, 10-20 parts of prepared rehmannia root, 10-20 parts of cassia twig, 10-20 parts of fructus ligustri lucidi, 10-20 parts of oldenlandia diffusa, 10-20 parts of radix ophiopogonis, 10-20 parts of the root of red-rooted salvia, 10-20 parts of carthamus tinctorius, 10-20 parts of radix paeoniae alba, 10-20 parts of pseudo-ginseng, 10-20 parts of astragalus mongholicus, 10-20 parts of prepared fleece flower root, 10-20 parts of poria cocos, 10-20 parts of vegetable sponge, 10-20 parts of ligusticum wallichii, 10-20 parts of curcuma zedoary, 10-20 parts of scutellaria baicalensis, 10-20 parts of albizia julibrissin, 10-20 parts of silkworm larva, 10-20 parts of angelica sinensis, and 10-20 parts of platycladi seeds. The traditional Chinese medicine preparation disclosed by the invention is capable of rapidly in-flowing blood, directly achieving myocardium and rapidly increasing myocardial contraction force and has the main functions of detoxifying, removing stasis, clearing heat, opening the inhibited lung-energy and clearing away the heart-fire; in addition, the functions of tonifying qi and calming the mind and the functions of soothing the liver and reducing heat are combined, the functions of rapidly relieving patient conditions and saving lives of patients are achieved.

The system and method may measure and monitor physiological changes in a body. In some embodiments, the system and method may measure the impedance at a site in the body. In some embodiments, the system and method identify, quantify, and localize leaks from a site following surgery, measure cardiac contractility, or lung compliance. In an embodiment, the system includes a measuring device with one or more sensors embedded in a porous matrix. Changes in the electrical properties of one or more sensors may be used to determine the presence of leaks from a site following surgery, measure cardiac contractility, or lung compliance, depending on the position of the device.

The invention discloses a traditional Chinese medicine composition for treating chronic cardiac failure and a preparation method thereof, applied to the field of traditional Chinese medicines. The traditional Chinese medicine composition comprises traditional Chinese medicine main ingredients and medicinal auxiliary materials, wherein the traditional Chinese medicine main ingredients comprise astragalus, cassia twig, salvia miltiorrhiza, Chinese angelica, ginseng, red flower, motherwort, semen lepidii, poria cocos and pseudo-ginseng; and the medicinal auxiliary materials comprise dextrin, starch and lactose. The preparation method comprises the following steps: heating, refluxing and extracting astragalus, ginseng, pseudo-ginseng, poria cocos, salvia miltiorrhiza and semen lepidii according to a prescription ratio by using ethanol twice, filtering, merging the filtrate, and recovering ethanol to obtain liquid medicine; soaking cassia twig, red flower, motherwort and Chinese angelica according to the prescription ratio, adding the obtained medicine residue, decocting by using water, filtering to obtain liquid medicine, decocting by using water, filtering to obtain liquid medicine, and collecting distillate twice to obtain the liquid medicine; performing spray drying on the concentrated solution, and preparing extract powder; and adding the extract powder into dextrin, uniformly mixing, wetting the granules by using ethanol to obtain a finished preparation. By adopting the method for tonifying qi, promoting blood circulation to remove blood stasis and warming yang to promote diuresis, the clinical symptoms of heart failure patients are improved, the myocardial contractility can be improved, and the pumped blood of venous return is increased, so that the heartbeat is increased, and the myocardial infarction range is narrowed.

A method and system is provided for determining the cardiac contractility of a cardiovascular system. The method includes utilizing values representing stroke volume, preload, and afterload to calculate the cardiac contractility. The calculation may include a mathematical relationship in which the cardiac contractility is represented by a first edge of a tetrahedron, the preload is represented by a second edge of the tetrahedron, the afterload is represented by a third edge of the tetrahedron, and the stroke volume is represented by the volume of the tetrahedron. A display apparatus is also provided. The display apparatus includes a schematic representation of a tetrahedron and indicia indicating that the cardiac contractility, the preload, the afterload, and the stroke volume are represented by mutually distinct parameters of the tetrahedron.

A cardiac electro-stimulatory device and method for operating same in which stimulation pulses are distributed among a plurality of electrodes fixed at different sites of the myocardium in order to reduce myocardial hypertrophy brought about by repeated pacing at a single site and / or increase myocardial contractility. In order to spatially and temporally distribute the stimulation, the pulses are delivered through a switchable pulse output configuration during a single cardiac cycle, with each configuration comprising one or more electrodes fixed to different sites in the myocardium.

The invention relates to a method for extracting Yulang block to obtain Yulang water extractive, alcohol extractive, polysaccharide and chromocor. Researches have proved that the Yulang water extractive, alcohol extractive, polysaccharide and chromocor can stably reduce hypertension, restrain heart muscle retraction, reduce heart muscle oxygen consumption, improve coronary flux and reduce myocardial ischemia refill hurt, while it can release breath, release the asthma caused by acetylcholine simulation, and resist the retraction of acetylcholine or ergamine on bronchi. And the Yulang water extractive and polysaccharide can resist senile dementia and hepatitis or the like. The invention supplies a novel Chinese drug for treating hypertension, coronary disease, or the like, without side effect.

A 3',4',5-trihydroxystlbene compound for lowering the high tension of arteria pulmonalis and improving respiratory function is disclosed. It includes polydatin (or piceid) and resveratnol prepared by hydrolyzing polydatin.

A combination cardiac stimulator for CRT stimulation and CCM stimulation, which is connected to a rhythm evaluation unit which can either detect a sinus rhythm that is present, or classify an atrial arrhythmia, and which comprises an additional therapy selection unit, wherein the therapy selection unit selects the delivery of either CRT therapy or CCM therapy on the basis of the classification of the atrial rhythm such that CRT therapy is preferred in the case of sinus rhythm, and CCM therapy is delivered in the case of atrial arrhythmia.

Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.

The invention discloses healthy tea rice porridge with a function of reducing blood pressure and a preparation method thereof. The tea rice porridge is prepared from 60-70 of millet, 20-30 of corn, 15-25 of green tea, 6-8 of peas, 3-5 of semen coicis, 1-3 of white sesame, 1-3 of kudzuvine root, 1-2 of fructus citri sarcodactylis, 0.8-1.2 of Japanese thistle root, 0.8-1.2 of immature bitter orange, 0.5-1 of pawpaw, 0.5-1 of pumpkin, 1-1.5 of Chinese dwarf cherry leaves, 1-1.5 of grosvenor momordica fruit leaves and white granulated sugar. The rice porridge produced by the preparation method has the advantages that the rice porridge has the special fragrance of tea and is tasty; the added kudzuvine root can inhibit excessive release of ET, promote endothelium recovery to excite PG12 synthetase activity, obviously increase EC to generate PG and inhibit platelet aggregation, and has the functions of improving blood circulation and reducing the blood pressure; the Japanese thistle root can reinforce myocardial contractility, improve heart functions, increase myocardial blood flow, dilate peripheral vessels, increase blood flow and reduce the blood pressure; and the product also contains various traditional Chinese medicine ingredients beneficial to human bodies, is suitable for people of all ages and is beneficial to body health after being eaten for a long time.

The invention relates to a food and particularly relates to a food composed of red dates and nut kernels and a manufacturing technology thereof. The manufacturing technology includes following steps: drying the red dates in sun; washing and sterilizing the red dates and soaking the red dates in fresh ginger water; baking surfaces of the red dates soaked in the fresh ginger water; pitting the red dates and cutting the hollow red dates into halves so that the red dates are cut into two connected parts; clamping a peeled nut kernel into interior of the hollow red dates; and then pressing the red dates and packaging the red dates. In the invention, because that the dried red dates are soaked in the fresh ginger water, the red dates has effects of removing cold and dampness from human body, can enhance muscle force, eliminate fatigue, expand blood vessels, enhance myocardial contractility and improve myocardial nutrition, and has an excellent effect on prevention and treatment of cardiovascular diseases. In addition, with addition of the nut kernels, the red date is not astringent and meanwhile a greasy taste of the nut kernels is avoided due to the red dates. Internal moisture of the red dates requires to be maintained within 80-90% so that a binding degree between the nut kernels and the dried red dates can be enhanced.

A micropill of danshinolic acid A for relaxating the smooth muscle of aorta, improving the left ventricular function and the cardiac pump function, and preventing and treating myocardial ischemia is prepared from danshinolic acid A or its pharmacologically acceptable salt and one or more medicinal auxiliaries. A capsule containing said micropills is also disclosed.

A physiological monitoring system features a Floormat and Handheld Sensor connected by a cable. A user stands on the Floormat and grips the Handheld Sensor. These components measure time-dependent physiological waveforms from a user over a conduction pathway extending from the user's hand or wrist to their feet. The Handheld Sensor and Floormat use a combination of electrodes that inject current into the user's body and collect bioelectric signals that, with processing, yield ECG, impedance, and bioreactance waveforms. Simultaneously, the Handheld Sensor measures photoplethysmogram waveforms with red and infrared radiation and pressure waveforms from the user's fingers and wrist, while the Floormat measures signals from load cells to determine ‘force’ waveforms to determine the user's weight, and ballistocardiogram waveforms to determine parameters related to cardiac contractility. Processing these waveforms with algorithms running on a microprocessor yield the vital sign, hemodynamic, and biometric parameters.

The invention relates to an application of natural compound epicatechin gallate obtained from tea and derivatives thereof for treating or preventing myocardial infarction and other ischemic heart diseases. The compound is used for preventing the myocardial injury of the heart caused by ischemia-reperfusion, and is a medicament for potentially treating or preventing the heart ischemia / reperfusion injury. Particularly, the compound has a novel effect on protecting the heart and has a function that the enhancement of the myocardial contractility does not depend on the increase of the concentration of calcium ions in myocardial cells. In the invention, it is discovered that the epicatechin gallate (ECG) and the derivatives thereof have pharmacological pre-adaptation functions and have pharmacological post-adaptation functions for the first time, thus the ECG and the derivatives thereof are possibly novel medicaments for treating or preventing myocardial infarction and other ischemic heart diseases. The ECG and the derivatives thereof not only can be used for clinically treating congestive heart diseases through pharmacological post-adaptation but also can be used for medically preventing the patient who suffers from myocardial infarction and then is cured from being subjected to myocardial infarction again through pharmacological pre-adaptation.